Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Effects of Intratympanic Gentamicin and Intratympanic Glucocorticoids in Ménière’s Disease: A Network Meta-Analysis of Randomized, Controlled Trials
46 Pages Posted: 15 Apr 2019
More...Abstract
Backgroud: Controversies exist in choosing Intratympanic gentamicin or intratympanic glucocorticoids for Ménière’s disease.
Methods: To assess the treatment effects and safety among intratympanic gentamicin, glucocorticoids and placebo therapy in Ménière disease. Electronic searches in PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, MEDLINE, BIOSIS Previews, Embase, CINAHL, ClinicalTrials.gov and the European Union Clinical Trials Register were conducted from inception until March 2019. All randomized controlled trials of intratympanic gentamicin or glucocorticoids for Ménière’s disease, compared with each other or placebo therapy, were considered for this review. Two independent reviewers extracted study data and performed quality assessment using the Cochrane Risk of Bias Tool. Network meta-analysis on vertigo control, function level scales (FLS), hearing outcomes and tinnitus handicap inventory (THI) were calculated with a Bayesian approach using the R package netmeta (version:3.5.2). The quality of primary outcomes was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
Findings: 10 studies of RCTs (455 patients) met inclusion criteria as described. Pooled results indicated significant advantage of intratympanic gentamicin and glucocorticoids over placebo treatments in vertigo control (gentamicin vs placebo: risk rate, RR, 2.56; 95%CI, 1.18 to 5.54; glucocorticoids vs placebo: RR, 3.02; 95%CI, 1.36 to 6.73). The comparison between gentamicin and glucocorticoids did not show a statistically significant result (RR 0.85; 95%CI, 0.69 to 1.03). FLS also showed improvements in intratympanic therapies over placebo. For PTA and SDS, intratympanic glucocorticoids showed better hearing protective results than gentamicin (change of PTA, MD, -6.48 dB; 95%CI, -11.84 dB to -1.13 dB; change of SDS, MD 7.69%; 95%CI, 0.83% to 14.55%),but no statistical significance in comparisons with placebo. No difference was found in THI among three approaches.
Interpretation: Intratympanic gentamicin and glucocorticoids are two effective approaches to control vertigo symptoms for Ménière’s disease. Compared with gentamicin, glucocorticoids showed a potentially better hearing protective role, and intratympanic gentamicin therapy was not associated with high risk of hearing loss than placebo.
Funding Statement: The authors have no funding to disclose.
Declaration of Interests: The authors have no financial relationships, or conflicts of interest to disclose.
Ethics Approval Statement: This research was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions, and the PRISMA extension statement for reporting of systematic reviews incorporating NMA of health care interventions. The pre-specified protocol of this systematic review has been registered in November 2018 (PROSPERO Identifier: CRD42018114389).
Suggested Citation: Suggested Citation